# A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.

> **NCT05361564** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 12 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Brigatinib

## Key facts

- **NCT ID:** NCT05361564
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06
- **Primary completion:** 2024-06
- **Final completion:** 2024-06
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2022-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05361564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05361564, "A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05361564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*